KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Non-Current Liabilities: 2020-2025

Historic Total Non-Current Liabilities for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $323.1 million.

  • AbCellera Biologics' Total Non-Current Liabilities rose 37.41% to $323.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.1 million, marking a year-over-year increase of 37.41%. This contributed to the annual value of $227.9 million for FY2024, which is 5.12% up from last year.
  • AbCellera Biologics' Total Non-Current Liabilities amounted to $323.1 million in Q3 2025, which was down 1.47% from $328.0 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Total Non-Current Liabilities ranged from a high of $328.0 million in Q2 2025 and a low of $83.0 million during Q1 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $228.3 million (2024), whereas its average is $243.5 million.
  • Data for AbCellera Biologics' Total Non-Current Liabilities shows a peak YoY surged of 140.66% (in 2021) over the last 5 years.
  • Over the past 5 years, AbCellera Biologics' Total Non-Current Liabilities (Quarterly) stood at $172.2 million in 2021, then increased by 9.96% to $189.3 million in 2022, then climbed by 14.50% to $216.8 million in 2023, then climbed by 5.12% to $227.9 million in 2024, then soared by 37.41% to $323.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $323.1 million for Q3 2025, versus $328.0 million for Q2 2025 and $245.8 million for Q1 2025.